EFPIA anti-counterfeiting pilot success could see industry recognise parallel traders as part of supply chain
This article was originally published in SRA
Executive Summary
Mass serialisation is a viable way of strengthening the supply chain and protecting against counterfeit medicines, a pilot launched by the European Federation of Pharmaceutical Industries and Associations has shown1. Furthermore, roll-out of such a verification system could prompt industry to recognise parallel traders as part of the supply chain.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.